|
MechanismEGFR exon 19 deletion inhibitors [+1] |
|
|
|
|
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunologic cytotoxicity [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 Vs. a Standard of Care EGFR TKI, As First Line Treatment to EGFR Mutation Positive Advanced NSCLC with CNS Metastases
The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with Central Nervous System (CNS) metastasis
100 Clinical Results associated with Alpha Biopharma (Jiangsu) Co., Ltd.
0 Patents (Medical) associated with Alpha Biopharma (Jiangsu) Co., Ltd.
100 Deals associated with Alpha Biopharma (Jiangsu) Co., Ltd.
100 Translational Medicine associated with Alpha Biopharma (Jiangsu) Co., Ltd.